Comprehensive analysis of cytokines and PD-L1 before and after administration of Atezolizumab and Bevasizumab in patients with HCC - ASTRAL-HCC

ational Center for Global Health and Medicine0 个研究点目标入组 20 人开始时间: 2021年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Current use of anticoagulants or antiplatelets or prior use within 10 days (2) High risk of bleeding or untreated/incompletely treated esophageal/gastric varix (3) Thrombosis or embolism within 180 days (4) Major surgery within 28 days (5) Use of immunostimulants within 180 days (6) Use of immunosuppressants within 14 days (7) Autoimmune disease within 180 days (8) Double cancer or prior malignant neoplasm except early malignancy (9) Enrollment to an intervention study or a study using unapproved drug (10) Severe cardiovascular disease, unstable arrhythmia, unstable angina within 90 days (11) Pregnancy, breastfeeding, no approve for contraception (12) Uncontrollable pleural effusion, pericardial fluid, or ascites (13) Hepatic encephalopathy (14) Uncontrollable hypertension, severe infection, hemodialysis (15) Allergy or anaphylactic reaction to chimeric antibody, humanized antibody, or fusion protein (16) Allergy to atezolizumab and bevasizumab (17) Current or prior active hemorrhagic disease (18) Oral feeding difficulty (19) HIV positivity (20) Active pulmonary fibrosis or interstitial pneumonia (21) Blood transfusion or G-CSF within 14 days (22) Unsuitable patient at a physician's decision

发起方

ational Center for Global Health and Medicine